Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alliance for Clinical Trials in Oncology
With
National Cancer Institute (NCI)
OBJECTIVES:
* To investigate the clinical relevance of conducting comprehensive molecular analyses on clinically annotated high-quality tumor biospecimens from patients with stage I or II, N0 or N1 (less than hilar) non-small cell lung cancer.
OUTLINE: This is a multicenter study.
Biological specimens are collected from participating clinical sites and analyzed by transcription profiling of RNA and microRNA; detection of DNA copy number changes and chromosomal rearrangements; epigenetic modifications analyses; and sequencing of genomic segments, genes, and regulatory regions to assess sequence variation. Clinical information associated with each specimen donor is also collected.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Diagnosis of non-small cell carcinoma
* Primary, untreated disease
* Stage I or II (T1 or T2, N0 or non-hilar N1, M0) disease
* Any of the following histologies allowed:
* Squamous cell carcinoma
* Adenocarcinoma (\< 10%)
* Large cell carcinoma (high-grade)
Available tumor tissue samples collected on clinical trial ACOSOG-Z0030 and meeting the following criteria:
* Snap-frozen and stored at a temperature of -80°C or lower
* Specimens may come from any site within the lung or one that is involved by direct regional extension of tumor from the originating site in the lung
No regional lymph node or distant metastases
No recurrent or persistent disease after prior neoadjuvant or adjuvant treatment for lung cancer
Must have matching frozen samples of normal tissue and blood